Cargando…
New drug developments in metastatic gastric cancer
Metastatic gastric cancer is associated with a poor prognosis and novel treatment options are desperately needed. The development of targeted therapies heralded a new era for the management of metastatic gastric cancer, however results from clinical trials of numerous targeted agents have been mixed...
Autores principales: | Tan, Aaron C., Chan, David L., Faisal, Wasek, Pavlakis, Nick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6236851/ https://www.ncbi.nlm.nih.gov/pubmed/30455742 http://dx.doi.org/10.1177/1756284818808072 |
Ejemplares similares
-
Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)
por: Tan, Aaron C., et al.
Publicado: (2022) -
New developments in the treatment of metastatic gastric cancer: focus on trastuzumab
por: Rose, Jeffrey S, et al.
Publicado: (2011) -
The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis
por: Chan, David L., et al.
Publicado: (2017) -
Vitamin E in Cancer Treatment: A Review of Clinical Applications in Randomized Control Trials
por: Donnelly, Jennifer, et al.
Publicado: (2022) -
Drug Development Against Metastatic Cancers
por: Wang, Chen, et al.
Publicado: (2017)